See more : Eco Innovation Group, Inc. (ECOX) Income Statement Analysis – Financial Results
Complete financial analysis of Immuron Limited (IMC.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuron Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Kamux Oyj (KAMUX.HE) Income Statement Analysis – Financial Results
- Jiangsu Zhongchao Holding Co., Ltd. (002471.SZ) Income Statement Analysis – Financial Results
- Jess-link Products Co., Ltd. (6197.TW) Income Statement Analysis – Financial Results
- BMW INDUSTRIES LIMITED (BMW.BO) Income Statement Analysis – Financial Results
- SpareBank 1 Nord-Norge (NONG.OL) Income Statement Analysis – Financial Results
Immuron Limited (IMC.AX)
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.90M | 1.80M | 765.19K | 145.78K | 2.52M | 2.39M | 1.84M | 1.40M | 1.00M | 1.00M | 981.05K | 149.76K | 449.01K | 213.95K | 461.89K | 524.10K | 292.90K | 4.25M | 4.00M | 4.87M | 3.68M | 0.00 | 1.98M | 488.23K | 0.00 | 0.00 |
| Cost of Revenue | 1.57M | 495.56K | 241.69K | 51.07K | 688.84K | 680.77K | 582.29K | 474.04K | 305.61K | 351.47K | 328.13K | 193.26K | 363.72K | 216.64K | 275.43K | 172.94K | 271.03K | 3.83M | 2.58M | 7.07M | 2.35M | 0.00 | 1.36M | 814.12K | 0.00 | 0.00 |
| Gross Profit | 3.34M | 1.31M | 523.50K | 94.71K | 1.83M | 1.71M | 1.26M | 922.16K | 695.47K | 650.91K | 652.92K | -43.50K | 85.30K | -2.69K | 186.46K | 351.17K | 21.87K | 418.90K | 1.43M | -2.20M | 1.32M | 0.00 | 618.75K | -325.88K | 0.00 | 0.00 |
| Gross Profit Ratio | 68.06% | 72.54% | 68.41% | 64.97% | 72.65% | 71.49% | 68.40% | 66.05% | 69.47% | 64.94% | 66.55% | -29.05% | 19.00% | -1.26% | 40.37% | 67.00% | 7.47% | 9.86% | 35.61% | -45.24% | 35.97% | 0.00% | 31.22% | -66.75% | 0.00% | 0.00% |
| Research & Development | 5.38M | 2.59M | 657.72K | 1.37M | 1.18M | 1.04M | 2.26M | 4.63M | 3.62M | 3.02M | 1.29M | 896.84K | 304.11K | 1.89M | 1.41M | 697.84K | 857.69K | 699.50K | 762.66K | 1.69M | 587.07K | 0.00 | 802.00K | 669.00K | 0.00 | 0.00 |
| General & Administrative | 4.52M | 4.22M | 3.52M | 6.09M | 3.12M | 4.93M | 3.34M | 1.34M | 1.30M | 515.80K | 457.19K | 551.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.03M | 927.42K | 416.54K | 287.68K | 871.55K | 864.64K | 686.71K | 1.33M | 756.34K | 497.86K | 429.25K | 8.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.55M | 5.15M | 3.92M | 6.38M | 4.04M | 5.90M | 4.10M | 4.68M | 5.33M | 1.91M | 1.51M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -2.79M | 430.93K | 0.00 | -759.76K | 11.34K | 38.41K | -163.60K | -136.49K | -4.18K | 0.00 | 0.00 | -4.09M | -3.69M | -4.78M | -3.86M | -4.02M | -4.87M | -5.72M | -6.56M | -2.05M | -4.01M | 0.00 | -3.33M | -2.26M | 0.00 | 0.00 |
| Operating Expenses | 9.14M | 7.31M | 4.58M | 8.51M | 5.22M | 6.36M | 4.25M | 7.71M | 7.43M | 3.46M | 2.77M | -3.20M | -3.39M | -2.89M | -2.45M | -3.32M | -4.01M | -5.02M | -5.80M | -352.98K | -3.42M | 0.00 | -2.52M | -1.59M | 0.00 | 0.00 |
| Cost & Expenses | 10.70M | 7.81M | 4.82M | 8.56M | 5.91M | 7.04M | 4.83M | 8.18M | 7.74M | 3.81M | 3.10M | -3.00M | -3.02M | -2.67M | -2.18M | -3.15M | -3.74M | -1.19M | -3.22M | 6.72M | -1.07M | 0.00 | -1.16M | -777.66K | 0.00 | 0.00 |
| Interest Income | 327.76K | 116.32K | 21.79K | 9.20K | 21.63K | 39.00 | 22.96K | 16.10K | 329.44K | 112.44K | 375.34K | 245.29K | 14.25K | 52.61K | 36.19K | 26.83K | 26.53K | 42.93K | 106.22K | 234.79K | 86.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.58K | 9.65K | 6.18K | 13.76K | 21.63K | 0.00 | 18.86K | 24.48K | 341.60K | 0.00 | 588.64K | 602.17K | 111.11K | 3.74K | 3.38K | 988.00 | 4.94K | 0.00 | 0.00 | 168.00 | 2.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 45.98K | 48.66K | 26.61K | 43.66K | 44.06K | 5.29K | 5.05K | 4.92K | 3.89K | 3.72K | 684.58K | 734.37K | 72.57K | 19.85K | 39.35K | 157.32K | 85.34K | 156.71K | 174.19K | 189.01K | 183.34K | 0.00 | 169.00K | 47.00K | 0.00 | 0.00 |
| EBITDA | -6.19M | -3.80M | -3.08M | -8.33M | -3.17M | -4.70M | -3.24M | -8.35M | -8.26M | -4.28M | -2.15M | -2.38M | -2.37M | -2.79M | -2.13M | -2.81M | -3.91M | -4.44M | -4.20M | -1.49M | -1.92M | 0.00 | -1.74M | -1.87M | 0.00 | 0.00 |
| EBITDA Ratio | -126.30% | -329.79% | -527.00% | -5,742.25% | -132.87% | -196.99% | -175.90% | -600.86% | -825.34% | -426.90% | -219.28% | -1,470.79% | -470.78% | -1,301.93% | -473.18% | -536.76% | -1,333.83% | -104.59% | -122.47% | -29.67% | -35.59% | 0.00% | -87.58% | -383.15% | 0.00% | 0.00% |
| Operating Income | -5.80M | -6.00M | -4.06M | -8.41M | -3.39M | -4.71M | -3.25M | -8.39M | -8.27M | -4.28M | -2.84M | -3.24M | -3.30M | -2.89M | -2.26M | -2.97M | -3.99M | -4.60M | -4.37M | -2.56M | -2.10M | 0.00 | -1.90M | -1.92M | 0.00 | 0.00 |
| Operating Income Ratio | -118.32% | -332.49% | -530.47% | -5,772.20% | -134.62% | -197.21% | -176.17% | -601.21% | -825.73% | -427.27% | -289.06% | -2,164.35% | -735.61% | -1,350.44% | -490.26% | -566.78% | -1,362.97% | -108.28% | -109.21% | -52.50% | -57.09% | 0.00% | -96.10% | -392.78% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.14M | -286.21K | -241.90K | -4.56K | -329.86K | 39.00 | -1.87M | 1.58M | 975.34K | 1.49M | -343.78K | -297.90K | 1.01M | 80.21K | 98.32K | 421.52K | 787.98K | 1.04M | 811.05K | 922.00K | 604.89K | 0.00 | 205.55K | 363.66K | 0.00 | 0.00 |
| Income Before Tax | -6.94M | -3.86M | -3.11M | -8.82M | -3.24M | -4.66M | -3.01M | -6.80M | -7.07M | -2.69M | -2.50M | -3.54M | -2.30M | -2.81M | -2.17M | -2.55M | -3.20M | -3.56M | -3.56M | -1.63M | -1.49M | 0.00 | -1.70M | -1.55M | 0.00 | 0.00 |
| Income Before Tax Ratio | -141.49% | -213.61% | -406.66% | -6,047.29% | -128.46% | -195.04% | -163.38% | -487.33% | -706.12% | -268.54% | -254.33% | -2,363.27% | -511.68% | -1,312.95% | -468.98% | -486.54% | -1,093.94% | -83.87% | -88.95% | -33.55% | -40.65% | 0.00% | -85.73% | -318.29% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -392.88K | -257.50K | -431.03K | -308.23K | -531.01K | -1.85M | -1.58M | -2.98M | 0.00 | 0.00 | 304.27K | 1.12M | -213.90K | -260.35K | 75.00K | -268.44K | -282.52K | -704.83K | -299.88K | -332.75K | 0.00 | 112.00 | -483.00 | 0.00 | 0.00 |
| Net Income | -6.94M | -3.79M | -2.85M | -8.38M | -2.93M | -4.66M | -3.01M | -6.80M | -7.07M | -2.69M | -2.50M | -3.54M | -2.30M | -2.60M | -1.91M | -2.32M | -2.86M | -3.28M | -3.56M | -1.33M | -1.16M | 0.00 | -1.70M | -1.55M | 0.00 | 0.00 |
| Net Income Ratio | -141.49% | -209.81% | -373.01% | -5,751.61% | -116.23% | -195.04% | -163.38% | -487.33% | -706.12% | -268.54% | -254.33% | -2,363.27% | -511.68% | -1,212.98% | -412.61% | -442.24% | -975.86% | -77.22% | -88.95% | -27.39% | -31.60% | 0.00% | -85.74% | -318.19% | 0.00% | 0.00% |
| EPS | -0.03 | -0.02 | -0.01 | -0.04 | -0.02 | -0.03 | -0.02 | -0.06 | -0.09 | -0.04 | -0.06 | -0.28 | -0.18 | -0.23 | -0.20 | -0.47 | -0.75 | -0.93 | -1.06 | -0.40 | -0.40 | -0.44 | -0.59 | -0.57 | -0.41 | -0.46 |
| EPS Diluted | -0.03 | -0.02 | -0.01 | -0.04 | -0.02 | -0.03 | -0.02 | -0.06 | -0.09 | -0.04 | -0.06 | -0.28 | -0.18 | -0.23 | -0.20 | -0.47 | -0.75 | -0.93 | -1.06 | -0.40 | -0.40 | -0.44 | -0.59 | -0.57 | -0.41 | -0.46 |
| Weighted Avg Shares Out | 227.86M | 227.80M | 227.58M | 221.06M | 176.39M | 144.74M | 133.66M | 105.87M | 76.44M | 74.94M | 41.96M | 12.79M | 12.42M | 11.38M | 9.48M | 4.92M | 3.80M | 3.54M | 3.34M | 3.30M | 2.93M | 2.92M | 2.86M | 2.73M | 2.40M | 1.50M |
| Weighted Avg Shares Out (Dil) | 227.86M | 227.80M | 227.58M | 221.06M | 176.39M | 144.74M | 133.66M | 105.87M | 76.44M | 74.94M | 41.96M | 12.79M | 12.42M | 11.38M | 9.48M | 4.92M | 3.80M | 3.54M | 3.34M | 3.30M | 2.93M | 2.92M | 2.86M | 2.73M | 2.40M | 1.50M |
Source: https://incomestatements.info
Category: Stock Reports